Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-07-02
DOI
10.1016/j.jaad.2021.06.869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
- (2020) Karen M. Page et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Emerging systemic drugs in the treatment of plaque psoriasis
- (2020) Esther A. Balogh et al. EXPERT OPINION ON EMERGING DRUGS
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
- (2020) Brian S Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study
- (2020) Ravi Shankar P. Singh et al. CTS-Clinical and Translational Science
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
- (2019) Tamara Pérez-Jeldres et al. Frontiers in Pharmacology
- JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
- (2019) Silvio Danese et al. GUT
- Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)
- (2019) Ryan Moslin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- (2019) Michael D. Howell et al. Frontiers in Immunology
- Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
- (2019) Amanda Kvist-Hansen et al. Dermatology and Therapy
- Can IL-23 be a good target for ulcerative colitis?
- (2018) Mariangela Allocca et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
- (2018) Elizabeth N. Ergen et al. EXPERIMENTAL DERMATOLOGY
- Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies
- (2018) Bani Ahluwalia et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon-Inducible Myxovirus Resistance Proteins: Potential Biomarkers for Differentiating Viral from Bacterial Infections
- (2018) Vladimir P. Zav’yalov et al. CLINICAL CHEMISTRY
- IL-23 in inflammatory bowel diseases and colon cancer
- (2018) Markus F. Neurath CYTOKINE & GROWTH FACTOR REVIEWS
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Apremilast for the management of moderate to severe plaque psoriasis
- (2017) Ramya Vangipuram et al. Expert Review of Clinical Pharmacology
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
- (2017) Duk Hwan Kim et al. Immune Network
- Innate lymphoid cells in inflammatory bowel diseases
- (2016) C.P. Peters et al. IMMUNOLOGY LETTERS
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Psoriasis
- (2016) Jacqueline E. Greb et al. Nature Reviews Disease Primers
- Psoriasis: classical and emerging comorbidities
- (2015) Maria de Fátima Santos Paim de Oliveira et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Immunopathogenesis of IBD: current state of the art
- (2015) Heitor S. P. de Souza et al. Nature Reviews Gastroenterology & Hepatology
- Update on psoriasis immunopathogenesis and targeted immunotherapy
- (2015) Satveer K. Mahil et al. Seminars in Immunopathology
- Economic Burden of Psoriasis in the United States
- (2015) Elizabeth A. Brezinski et al. JAMA Dermatology
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
- (2014) Philip J. Mease et al. DRUGS
- Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
- (2014) Hajime Akada et al. STEM CELLS
- Tyk2 is a therapeutic target for psoriasis-like skin inflammation
- (2013) M. Ishizaki et al. INTERNATIONAL IMMUNOLOGY
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
- (2013) S. J. Sohn et al. JOURNAL OF IMMUNOLOGY
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
- (2013) Sung O. Park et al. PLoS One
- Patients with Psoriasis Feel Stigmatized
- (2012) JC Szepietowski et al. ACTA DERMATO-VENEREOLOGICA
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011
- (2012) April W. Armstrong et al. PLoS One
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3: A two-faced player in hematological disorders
- (2009) Melanie G. Cornejo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin Stimulates Both JAK2-dependent and JAK2-independent Signaling Pathways
- (2008) Lin Jiang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search